Product Information
SAXAGLIPTIN-METFORMIN ER 5-1,000 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $9.6470 per EA under NDC 00378817793. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Jul 31, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1000; 5 mg/1; mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378817793
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE DIHYDRATEApproval Type
Generic (ANDA)
FDA Application
ANDA205981FDA Approved
7/31/2023
TE Code
AB
On Market Since
8/8/2023
Pharmacological Classes
Price Statistics
The NADAC for SAXAGLIPTIN-METFORMIN ER 5-1,000 MG TABLET has been published 129 times since Apr 17, 2024, and over the history we have for it it has risen 7.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.6470 per EA |
|---|---|
| All-time high | $10.6076 (Apr 15, 2026) |
| All-time low | $8.4798 (May 22, 2024) |
| 52-week high | $10.6076 |
| 52-week low | $9.4868 |
| Median price | $9.8635 |
| Average price | $9.7998 |
| Largest weekly change | +11.4% (Jun 19, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the saxagliptin and metformin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
saxagliptin and metformin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SAXAGLIPTIN-METFORMIN ER 5-1,000 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SAXAGLIPTIN-METFORMIN ER 5-1,000 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $9.6470 per EA (NDC 00378817793), effective Sep 30, 2026.
How has the price of SAXAGLIPTIN-METFORMIN ER 5-1,000 MG TABLET changed over time?
Over the history we have for it, the NADAC for SAXAGLIPTIN-METFORMIN ER 5-1,000 MG TABLET has risen 7.6%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for SAXAGLIPTIN-METFORMIN ER 5-1,000 MG TABLET?
Since Apr 17, 2024, the NADAC for SAXAGLIPTIN-METFORMIN ER 5-1,000 MG TABLET has ranged from a low of $8.4798 (May 22, 2024) to a high of $10.6076 (Apr 15, 2026), with a median of $9.8635 per EA.
Are there cheaper alternatives to SAXAGLIPTIN-METFORMIN ER 5-1,000 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of SAXAGLIPTIN-METFORMIN ER 5-1,000 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SAXAGLIPTIN-METFORMIN ER 5-1,000 MG TABLET?
SAXAGLIPTIN-METFORMIN ER 5-1,000 MG TABLET (NDC 00378817793) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.